The German ONKOPEDIA Guideline for Myelofibrosis in 2025—Recommendations of an MPN Expert Panel of the German Society for Hematology and Oncology ( DGHO )
International Journal of Cancer · 01.10.2026 · 159 (7) · 1633-1641
DOI: 10.1002/ijc.70595 ↗Kurz gefasst
Leitlinie in der Zeitschrift International Journal of Cancer, online erschienen am 21.06.2026. Verfasst von Martin Griesshammer und 8 weiteren Autor:innen. Beteiligte Einrichtung: University Clinic for Hematology, Oncology, Haemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden…. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Myeloproliferative Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The recently published ONKOPEDIA guideline on myelofibrosis, issued under the auspices of the German Society of Hematology and Oncology (DGHO), provides an updated, evidence‐based framework for the diagnosis and management of this rare, chronic myeloproliferative neoplasm. Developed by a panel of experts (including Germany, Austria and Switzerland) nominated by the DGHO, the guideline reflects a structured and consensus‐oriented process in which internationally recognized specialists in hematology critically reviewed the available evidence, revised the written draft, and engaged in multiple rounds of discussion to ensure consistency, clinical relevance, and scientific rigor. This update builds upon the foundation of the previously available ONKOPEDIA guideline (accessible at www.onkopedia.com ), but extends and refines the recommendations in light of several important recent developments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University Clinic for Hematology, Oncology, Haemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany.
- Krukenberg Cancer Center, University Hospital of Halle, Halle, Germany.
- Clinic for Hematology and Oncology, Hirslanden Zürich AG, Zürich, Switzerland.
- Medica Medical Laboratories and Pathology, Medizinische Laboratorien Dr. F. Kaeppeli AG, Zürich, Switzerland.
- Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany.
- Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
ORCID-Profile: Florian H Heidel
Zitieren
APA
Griesshammer, M., Al-Ali, H. K., Baerlocher, G. M., Döhner, K., Koschmieder, S., Kröger, N., Petrides, P. E., Wolf, D., & Heidel, F. H. (2026). The German ONKOPEDIA Guideline for Myelofibrosis in 2025—Recommendations of an MPN Expert Panel of the German Society for Hematology and Oncology ( DGHO ). International Journal of Cancer, 159(7), 1633-1641. https://doi.org/10.1002/ijc.70595
Vancouver
Griesshammer M, Al-Ali HK, Baerlocher GM, Döhner K, Koschmieder S, Kröger N, et al. The German ONKOPEDIA Guideline for Myelofibrosis in 2025—Recommendations of an MPN Expert Panel of the German Society for Hematology and Oncology ( DGHO ). International Journal of Cancer. 2026;159(7):1633-1641. doi:10.1002/ijc.70595
BibTeX
@article{Griesshammer2026,
author = {Griesshammer, Martin and Al-Ali, Haifa Kathrin and Baerlocher, Gabriela M and Döhner, Konstanze and Koschmieder, Steffen and Kröger, Nicolaus and Petrides, Petro E and Wolf, Dominik and Heidel, Florian H},
title = {The German ONKOPEDIA Guideline for Myelofibrosis in 2025—Recommendations of an MPN Expert Panel of the German Society for Hematology and Oncology ( DGHO )},
journal = {International Journal of Cancer},
year = {2026},
volume = {159},
number = {7},
pages = {1633--1641},
doi = {10.1002/ijc.70595}
}
EUVIMED